BiotechTube
Eolas Therapeutics

Eolas Therapeutics

Dublin, United States· Est.
eolasthera.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $25M

Overview

Eolas Therapeutics is a private, clinical-stage biotech founded in 2018, headquartered in Dublin, United States. The company is advancing a pipeline of three drug candidates targeting substance use disorders, with its lead asset, AZD-4041 for Opioid Use Disorder, in Phase II. Eolas's strategy is built on a neuroscience platform focused on modulating neural reward pathways and is supported by non-dilutive funding from grants and strategic partnerships, such as its agreement with AstraZeneca.

NeuroscienceOncology

Technology Platform

Neuroscience platform focused on modulating specific neural pathways within the brain's reward system to treat addiction and related disorders.

Funding History

2
Total raised:$25M
Series A$20M
Seed$5M

Opportunities

The company is targeting large, underserved markets in substance use disorders, including Opioid Use Disorder (a public health crisis) and Cocaine Use Disorder (with no FDA-approved pharmacotherapy).
Significant non-dilutive grant funding from the NIH de-risks development and validates the unmet need.
The strategic partnership with AstraZeneca provides access to a late-stage asset and potential future collaboration.

Risk Factors

High risk of clinical trial failure inherent to all drug development, particularly in the complex field of neuroscience and addiction.
The pipeline is concentrated in a single, challenging therapeutic area, creating concentration risk.
As a pre-revenue private company, future financing needs and potential dilution remain a key uncertainty.

Competitive Landscape

Competition in addiction treatment includes existing approved therapies (e.g., buprenorphine, naltrexone for OUD) and other biotechs developing novel mechanisms. For Cocaine Use Disorder, the landscape is sparse, offering a first-in-class opportunity but also requiring pioneering clinical development. Eolas's focus on the neural reward system provides a differentiated scientific approach.

More companies in Neuroscience & CNS →More companies in United States →